No strong association is found between pioglitazone and bladder cancerBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h3934 (Published 22 July 2015) Cite this as: BMJ 2015;351:h3934
- Jacqui Wise
The diabetes drug pioglitazone is not associated with a statistically significant increased risk of bladder cancer, although a small increased risk cannot be excluded, new research published in JAMA has found.1
The researchers also found that the use of pioglitazone was associated with a higher risk of prostate and pancreatic cancer, although they said that further investigation is needed to assess whether the associations are causal or due to other factors.
The safety of pioglitazone, an oral antidiabetic agent in the thiazolidinedione class, is controversial. Preclinical studies of the drug in the 1990s showed an increase in bladder cancer in male rats, and early clinical …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial